Brookline Capital (BCAC) Shareholders Approve Apexigen Deal
by Marlena Haddad on 2022-07-28 at 7:19am

Brookline Capital (NASDAQ:BCAC) announced in an 8-K this morning that its shareholders approved its combination with Apexigen at a special meeting July 27.

The filing did not include redemption figures, but the transaction also did not have a minimum cash condition beyond listing requirements. Brookline brought a $15 million PIPE alongside its trust in the deal and Lincoln Park also agreed to purchase up to $50 million of the combined entity’s stock in the two years following the transaction’s close.

Brookline traded below its estimated pro rata trust value of $10.22 throughout its July 25 redemption deadline, but has since soared to a close Wednesday at $10.75. Following the deal’s close, Apexigen is expected to trade on the Nasdaq under the symbol “APGN”.

The parties initially announced the $278 million combination on March 18. San Carlos, California-based Apexigen is developing a range of immunological cancer treatments with four currently in Phase II trials.

It announced the results of its Phase II trials to treat pancreatic cancer with its sotigalimab drug candidate in June.


ADVISORS

  • Brookline Capital Markets is acting as capital markets advisor to Brookline Capital Acquisition Corp.
  • Wedbush PacGrow is acting as exclusive strategic financial advisor to Apexigen.
  • DLA Piper LLP (US) is serving as legal advisor to Brookline Capital Acquisition Corp.
  • Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal advisor to Apexigen.
Recent Posts
by Nicholas Alan Clayton on 2024-04-25 at 8:04am

At the SPAC of Dawn There are signs that the macro environment for SPACs is gradually improving, but the Screaming Eagle team yesterday announced a non-redemption agreement for its combination with Lionsgate Studios. Such agreements are generally a lever one pulls when a SPAC expects a potentially turbulent closing. All in all, the terms for...

by Nicholas Alan Clayton on 2024-04-24 at 4:09pm

Israeli tech firms have made up an outsized proportion of SPAC activity and despite the ongoing tensions in its region, that dealmaking is continuing unabated. In fact, the SPAC named for the particular mission of taking Israeli firms public through SPACs, Israel Acquisition Corp. (NASDAQ:ISRL) in fact just took one step closer in completing that...

by Nicholas Alan Clayton on 2024-04-24 at 8:07am

At the SPAC of Dawn Although the market has largely recovered from a negative stretch last week, the roller coaster is tilted back downward for Trump Media (NASDAQ:DJT), which slid -8% yesterday to $32.57 – one of its lowest points since closing with Digital World last month. Other SPACs and de-SPACs are having a more...

by Nicholas Alan Clayton on 2024-04-23 at 4:05pm

Remember the metaverse? Many do not. Meta’s (NASDAQ:META) attempted transition to virtually living and working seemed to mark a trend that went up and down quickly, but one SPAC deal has both survived that roller coaster and may rise with a second. Back in December 2022, Newbury Street (NASDAQ:NBST) announced a $1.85 billion combination with...

by Nicholas Alan Clayton on 2024-04-23 at 7:50am

At the SPAC of Dawn Tucked into the bill that provides $95 billion in funding to American allies passed by the House this weekend is another measure that is likely to have far more impact on at least one pending deal in SPAC world. It would appear that the timing was fortuitous for TikTok rival...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved